rubella
virus
rv
found
associ
granuloma
children
primari
immun
defici
pid
report
recoveri
character
infecti
immunodeficiencyrel
vaccinederiv
rubella
virus
ivdrv
diagnost
skin
biopsi
four
patient
sequenc
evolut
within
pid
host
studi
comparison
complet
genom
sequenc
ivdrv
genom
vaccin
viru
degre
diverg
ivdrv
correl
durat
persist
indic
continu
intrahost
evolut
evolut
rate
synonym
nonsynonym
substitut
estim
x
subssiteyear
x
subssiteyear
respect
mutat
spectra
signatur
indic
major
role
apobec
cytidin
deaminas
secondari
role
adar
adenosin
deaminas
gener
divers
ivdrv
distribut
mutat
across
gene
hotspot
amino
acid
substitut
glycoprotein
identifi
region
may
posit
select
pressur
quasispeci
divers
higher
granuloma
recov
infecti
ivdrv
growth
properti
ivdrv
assess
fibroblast
cultur
none
ivdrv
isol
show
complet
revers
wild
type
plo
pathogen
http
doi
introduct
rubella
viru
rv
envelop
singlestrand
positivesens
rna
viru
rubiviru
genu
recent
move
togavirida
new
famili
matonavirida
total
rv
genotyp
repres
clade
recogn
genotyp
current
common
worldwid
rv
replic
low
level
produc
littl
cytopatholog
vitro
vivo
distinct
featur
rv
abil
persist
placenta
fetu
immun
privileg
bodi
site
immunolog
compet
individu
persist
rv
infect
associ
congenit
rubella
syndrom
cr
number
less
common
patholog
rubella
enceph
fuch
uveiti
live
attenu
vaccin
strain
viru
like
extinct
genotyp
part
mmr
vaccin
current
use
us
global
high
immunogen
gener
longterm
immun
singl
dose
effect
prevent
clinic
diseas
low
rate
advers
event
worldwid
implement
rubella
vaccin
program
result
elimin
rubella
cr
america
signific
reduct
burden
diseas
develop
countri
similar
wild
type
rv
persist
immunolog
compet
individu
limit
time
caus
mild
complic
transient
arthralgia
arthriti
adult
women
vaccin
viru
involv
patholog
fuch
uveiti
also
suspect
vaccin
viru
associ
congenit
defect
asymptomat
persist
infect
fetu
report
inadvert
vaccin
unknowingli
pregnant
women
primari
immunodefici
diseas
pid
group
hereditari
disord
affect
differ
arm
immun
system
pid
patient
usual
increas
suscept
infect
difficulti
elimin
pathogen
live
vaccin
includ
rubella
vaccin
contraind
individu
sever
antibodi
defici
tcell
defici
innat
immun
defect
may
caus
sever
chronic
diseas
unfortun
pid
diagnosi
often
occur
vaccin
mmr
usual
given
age
month
nevertheless
advers
outcom
relat
mmr
vaccin
children
diagnos
pid
thought
rare
granuloma
format
wellrecogn
diseas
pid
patient
accumul
histiocyt
immun
cell
near
site
chronic
infect
may
persist
year
sometim
result
signific
patholog
estim
granuloma
preval
pid
patient
individu
us
expect
affect
rv
antigen
rna
recent
found
associ
granuloma
variou
bodi
site
skin
liver
kidney
spleen
lung
bone
periosteum
children
broad
spectrum
pid
rv
posit
cutan
granuloma
report
develop
week
averag
week
mmr
vaccin
typic
near
vaccin
site
also
appear
bodi
site
eg
face
leg
slowli
spread
promin
cell
defici
often
concurr
antibodi
defici
common
characterist
pid
patient
rv
posit
granuloma
immunohistochem
analysi
granulomat
lesion
reveal
macrophag
center
granuloma
commonli
harbor
rv
antigen
previous
mutat
rna
detect
case
sequenc
data
limit
result
littl
known
evolut
vaccin
viru
persist
infect
pid
patient
initi
attempt
isol
infecti
viru
rvposit
skin
granuloma
singl
pid
patient
fail
accumul
deleteri
mutat
vaccin
viru
persist
case
may
caus
loss
infect
viru
howev
unclear
whether
loss
infect
common
featur
virus
within
pid
patient
characterist
vaccin
viru
evolut
within
particular
patient
report
isol
infecti
immunodeficiencyrel
vaccinederiv
rubella
virus
ivdrv
skin
biopsi
four
pid
patient
collect
differ
time
vaccin
determin
full
genom
sequenc
ivdrv
character
chang
rel
parent
viru
object
character
evolut
persist
infect
pid
patient
replic
persist
properti
recov
ivdrv
compar
wild
type
rv
wtrv
primari
human
fibroblast
use
cultur
attenu
studi
also
document
ivdrv
detect
nasopharyng
secret
rais
possibl
transmiss
ivdrv
strain
suscept
nonimmun
contact
real
time
rtqpcr
analysi
reveal
variabl
amount
rv
rna
skin
biopsi
four
pid
patient
rang
total
rv
rna
copi
per
biopsi
sampl
tabl
measl
mump
rna
detect
rna
sampl
realtim
rtpcr
consist
result
previous
report
granuloma
case
furthermor
rv
antigen
detect
avail
tissu
section
cutan
granuloma
la
ri
case
fluoresc
immunohistochem
stain
measl
rubella
antigen
fig
data
indic
rubella
compon
mmr
vaccin
persist
four
lesion
whorecommend
protocol
rv
isol
requir
three
passag
infect
fresh
vero
cell
monolay
media
previou
weeklong
passag
tabl
taken
togeth
data
suggest
infecti
virus
distinct
growth
properti
present
lesion
four
patient
presenc
infecti
viru
biopsi
led
us
assess
viru
shed
urin
sampl
np
swab
buccal
swab
lesion
scrape
first
test
rv
rna
realtim
rtqpcr
sampl
neg
except
two
sequenti
np
swab
taken
three
week
apart
la
case
patient
tabl
rv
rna
concentr
np
swab
low
copiesml
swab
sampl
viru
cultur
use
ml
sampl
rv
rna
moleculesflask
unsuccess
probabl
due
low
number
infecti
particl
sampl
ratio
foci
form
unit
ffu
per
rv
genom
previous
determin
wtrvinfect
cell
cultur
lower
clinic
sampl
thu
estim
ffu
per
flask
less
two
isol
attempt
presenc
rv
rna
sequenti
np
sampl
indic
viral
shed
nasopharyng
caviti
occur
three
sera
one
pbmc
sampl
three
patient
neg
rtqpcr
indic
lack
viremia
full
genom
sequenc
obtain
granuloma
biopsi
specimen
rv
passag
viru
isol
rvi
sanger
sequenc
overlap
rtpcr
product
isol
passag
three
time
obtain
high
titer
viru
stock
consensu
sequenc
full
rv
genom
stock
ident
show
consensu
sequenc
stabil
least
three
passag
vero
cell
phylogenet
analysi
sequenc
obtain
primari
granuloma
sampl
includ
previous
describ
rv
genebank
full
genom
rv
refer
virus
show
sequenc
deriv
patient
sampl
belong
genotyp
fig
vaccin
strain
basal
sequenc
ivdrv
virus
somewhat
distantli
relat
vaccin
strain
also
genotyp
compar
analysi
six
ivdrv
rv
four
rvi
genom
sequenc
reveal
multipl
singl
nucleotid
substitut
compar
parent
viru
mani
nonsynonym
fig
tabl
data
amino
acid
substitut
ivdrv
protein
observ
total
posit
tabl
major
substitut
total
found
ivdrv
strain
wherea
remain
substitut
amino
acid
posit
also
observ
variou
wtrv
strain
may
repres
revers
wtrv
notabl
substitut
occur
invari
amino
acid
wtrv
circul
worldwid
period
tabl
data
thu
spectrum
amino
acid
substitut
appear
differ
wtrv
circul
normal
popul
ivdrv
persist
immunodefici
individu
tabl
addit
studi
cross
section
divers
need
confirm
observ
consensu
rvi
genom
sequenc
four
isol
differ
pair
rv
sequenc
deriv
directli
granuloma
biopsi
fig
differ
presum
mani
virus
patient
granuloma
enter
andor
replic
vero
cell
addit
doubl
peak
occur
multipl
posit
rv
chromatogram
indic
presenc
mix
nucleotid
sequenc
ambigu
minim
rvi
genet
relationship
consensu
genom
sequenc
origin
granuloma
sampl
whole
genom
refer
virus
infer
use
maximum
likelihood
method
taxa
label
name
ivdrv
sequenc
mark
red
dot
genet
distanc
comput
use
maximum
composit
likelihood
method
scale
bar
indic
number
base
substitut
per
site
ivdrv
repres
separ
branch
tree
basal
chromatogram
data
show
exist
differ
popul
virus
quasispeci
tissu
clinic
isol
attempt
lab
use
next
gener
sequenc
techniqu
deep
sequenc
rv
genom
directli
clinic
sampl
unsuccess
far
sequenc
depth
rare
exceed
probabl
low
quantiti
viral
rna
clinic
sampl
high
gc
content
rv
genom
strong
genom
secondari
structur
henc
character
viral
divers
molecular
clone
follow
sanger
sequenc
select
granuloma
biopsi
ca
case
pair
viru
stock
comparison
rv
genet
variabl
origin
clinic
sampl
versu
viru
isol
largest
differ
rvi
rv
consensu
sequenc
delet
total
substitut
rvi
rel
rv
nonsynonym
gene
fragment
amplifi
high
fidel
dna
polymeras
use
total
rna
isol
granuloma
biopsi
viral
stock
clone
sequenc
total
rv
rvi
clone
sequenc
analyz
divers
complex
genet
divers
within
quasispeci
origin
granuloma
specimen
mean
max
genet
distanc
higher
viru
stock
mean
max
genet
distanc
data
low
complex
observ
viru
stock
ident
sequenc
wherea
ivdrv
quasispeci
granuloma
highli
heterogen
found
two
peak
distribut
pairwis
genet
distanc
individu
quasispeci
fig
data
withinpati
phylogenet
analysi
quasispeci
confirm
two
distinct
ivdrv
subpopul
present
granuloma
lesion
fig
quasispeci
viru
stock
group
togeth
quasispeci
lesion
subpopul
explain
differ
consensu
sequenc
rv
rvi
case
one
synonym
substitut
quasispeci
isol
compar
consensu
sequenc
quasispeci
granuloma
subpopul
taken
togeth
data
demonstr
complex
popul
structur
ivdrv
quasispeci
granuloma
lesion
small
subset
quasispeci
infecti
vero
cell
cultur
relationship
number
synonym
nonsynonym
substitut
rv
genom
sequenc
case
time
vaccin
present
fig
constant
increas
number
substitut
per
rv
genom
time
indic
continu
sequenc
evolut
ivdrv
pid
patient
overal
trend
posit
linear
associ
number
synonym
nonsynonym
substitut
durat
persist
thu
either
substitut
type
may
use
molecular
clock
determin
time
ivdrv
genom
persist
patient
distribut
pairwis
genet
distanc
individu
quasispeci
within
primari
granuloma
sampl
viru
isol
ca
patient
bar
bin
histogram
repres
number
comparison
distanc
class
note
distanc
categori
ident
due
round
underli
data
found
data
file
c
neighborjoin
tree
nonroot
quasispeci
within
granuloma
sampl
n
blue
circl
viru
isol
n
red
circl
ca
case
genet
distanc
comput
use
maximum
composit
likelihood
method
scale
bar
indic
number
base
substitut
per
site
sinc
sequenc
vaccin
viru
time
vaccin
administr
known
rate
evolut
ivdrv
strain
calcul
direct
pairwis
comparison
ivdrv
rv
genom
sequenc
sequenc
ancestor
vaccin
use
snap
estim
ivdrv
evolut
rate
vari
slightli
among
patient
tabl
averag
ds
rate
x
subssiteyear
averag
dn
rate
x
subssiteyear
ds
rate
similar
gene
dn
rate
differ
among
gene
overal
ivdrv
evolut
rate
estim
x
subssiteyear
consensu
genom
sequenc
protein
sequenc
ivdrv
anatom
separ
bodi
site
arm
skin
np
caviti
la
case
substanti
differ
fig
indic
coexist
differ
ivdrv
lineag
patient
phylogenet
tree
fig
show
genet
relationship
full
genom
two
lineag
lagr
lanp
use
determin
ds
dn
rate
estim
two
lineag
year
year
respect
mmr
synonym
substitut
distribut
evenli
throughout
genom
nonsynonym
substitut
occur
predomin
gene
encod
structur
protein
hypervari
region
gene
fig
evalu
select
pressur
individu
rv
gene
calcul
dnd
ratio
rv
gene
patient
fig
calcul
dnd
ratio
one
mean
estim
presenc
direct
select
overal
sp
gene
less
constrain
diverg
nsp
gene
sinc
differ
function
structur
domain
protein
often
differ
select
pressur
evolv
differ
rate
examin
evolutionari
pattern
ivdrv
protein
calcul
cumul
behavior
averag
dn
ds
per
codon
move
codon
codon
along
gene
fig
data
ds
curv
similar
differ
gene
along
gene
length
repres
baselin
mutat
fixat
synonym
mutat
larg
neutral
increas
cumul
substitut
index
howev
differ
substanti
gene
differ
region
gene
region
constant
cumul
dn
valu
indic
strong
purifi
select
mostli
defin
conserv
protein
domain
eg
methyltransferas
adpribos
bind
proteas
domain
gene
entir
gene
encod
rnadepend
rna
polymeras
rdrp
glycoprotein
conserv
among
sp
protein
domain
appear
strong
neg
pressur
except
first
residu
similar
dn
ds
curv
ntermin
half
capsid
c
protein
suggest
neutral
evolut
region
respons
associ
genom
rv
rna
ctermin
part
c
protein
appear
purifi
select
function
domain
yet
clear
c
protein
shown
enhanc
rv
replic
interact
number
cellular
protein
inhibit
apoptosi
specif
amino
acidsdomain
involv
interact
determin
evolut
protein
appear
neutral
sinc
dn
ds
curv
similar
altern
protein
could
subject
diversifi
purifi
select
region
aa
nonsynonym
mutat
predomin
could
posit
select
unfortun
function
structur
domain
defin
detail
infecti
vaccinederiv
rubella
virus
immunodefici
data
second
major
compon
mutat
spectrum
utoc
substitut
smaller
number
ctou
utoc
chang
rv
neg
strand
posit
strand
express
gtoa
atog
chang
posit
strand
fig
mutat
profil
strand
bia
agre
previous
suggest
role
apobec
apolipoprotein
b
mrna
edit
enzym
catalyt
polypeptidelik
cytidin
deaminas
adar
adenosin
deaminas
act
rna
gener
nucleotid
divers
rna
virus
use
webbas
tool
inosinepredict
gener
predict
score
mutagenesi
adenosin
ivdrv
rv
genom
sequenc
support
enzym
play
role
mutat
adenin
viral
dna
predict
score
posit
contain
g
mutat
exceed
predict
score
adenin
posit
mutat
contain
mutat
g
fig
data
mutat
cytosin
viral
posit
strand
fig
capabl
cytidin
deamin
rna
well
establish
apobec
enzym
commonli
view
act
exclus
dna
howev
recent
report
suggest
subfamili
might
also
act
pathogen
host
rna
certain
type
cell
prefer
motif
deamin
ccn
n
nucleotid
mutat
nucleotid
capit
member
famili
well
character
prefer
tcn
motif
higher
prefer
tcw
w
diagnost
signatur
narrow
tca
trinucleotid
therefor
explor
enrich
mutat
signatur
ctou
mutat
induc
posit
strand
six
ivdrv
rv
sequenc
interestingli
ivdrv
strain
well
total
mutat
catalogu
deplet
ccn
motif
characterist
howev
strong
enrich
tcnspecif
signatur
constitut
around
mutat
posit
strand
split
tcn
signatur
subcompon
even
higher
prefer
apobec
enzym
reveal
enrich
tca
signatur
exceed
enrich
either
tcn
tcw
fig
data
enrich
tcn
tcw
tca
signatur
highli
statist
signific
pvalu
onesid
fisher
exact
test
case
see
tab
data
file
indic
one
u
cnspecif
apobec
play
role
gener
divers
ivdrv
popul
addit
studi
also
need
understand
connect
dynam
viral
rna
secondari
structur
rel
impact
apobec
adar
edit
activ
act
mutual
exclud
substratessingl
strand
doubl
strand
state
viral
rna
fold
mani
amino
acid
chang
occur
c
protein
interpret
function
signific
limit
known
function
domain
rv
structur
protein
glycoprotein
play
crucial
role
rv
infect
mediat
receptor
bind
membran
fusion
better
immunogen
c
four
neutral
epitop
map
protein
least
one
weak
neutral
epitop
identifi
precis
map
less
known
rubellaspecif
mhc
class
restrict
ctl
respons
three
cell
epitop
identifi
far
two
overlap
locat
capsid
protein
chang
rv
neutral
b
cell
epitop
cell
epitop
detect
case
except
ri
case
tabl
sinc
data
antigen
structur
c
protein
limit
detail
analysi
mutat
perform
three
dimension
structur
rv
strain
recent
solv
amino
acid
sequenc
glycoprotein
strain
belong
genotyp
ident
gain
insight
drive
forc
evolut
within
pid
patient
map
amino
acid
substitut
occur
rv
rvi
onto
spatial
structur
singl
chain
fig
tabl
analysi
reveal
two
mutat
hotspot
spatial
structur
defin
cluster
commonli
mutat
residu
van
der
waal
contact
one
anoth
mutat
hotspot
involv
residu
vicin
neutral
epitop
none
hotspot
substitut
except
present
infecti
viru
isol
suggest
mutat
may
detriment
rv
infect
cell
cultur
mutat
hotspot
ii
includ
hydrophob
residu
residu
locat
near
fusion
loop
two
tabl
u
c
chang
posit
strand
axi
denot
predict
score
activ
express
black
horizont
line
graph
denot
median
valu
predict
score
pvalu
shown
scatter
plot
c
enrich
apobec
edit
motif
ivdrv
rv
genom
mutat
nucleotid
shown
capit
letter
within
trinucleotid
mutat
motif
enrich
valu
calcul
c
u
mutat
induc
rv
posit
strand
describ
method
pvalu
onesid
fisher
exact
test
calcul
describ
found
tab
data
file
substitut
share
ivdrv
revers
wt
occur
five
six
ivdrv
substitut
occur
six
ivdrv
wtrv
strain
tabl
mani
mutat
residu
total
expos
surfac
fig
tabl
thu
could
involv
direct
interact
host
molecul
sever
substitut
occur
neutral
epitop
three
ivdrv
strain
epitop
invari
tabl
substitut
epitop
two
mutat
epitop
locat
propos
membran
contact
region
close
proxim
fusion
loop
substitut
aa
posit
epitop
cooccur
three
ivdrv
strain
thu
might
import
interact
neutral
antibodi
spatial
locat
epitop
near
fusion
loop
suggest
antibodi
target
epitop
may
neutral
rv
infect
interf
fusion
process
thu
prevent
cell
entri
substitut
map
epitop
locat
close
proxim
epitop
similar
expos
surfac
trimer
neutral
mechan
antibodi
target
mostli
like
similar
mechan
propos
interfer
format
trimer
prefus
form
taken
togeth
data
suggest
granulomaassoci
rubella
viru
select
pressur
neutral
antibodi
cell
replic
persist
properti
vaccin
clinic
isol
form
acut
rv
infect
substanti
differ
test
vaccinederiv
virus
granuloma
chang
vaccin
phenotyp
compar
growth
properti
four
ivdrv
strain
growth
properti
rvdz
human
fetal
fibroblast
primari
cell
cultur
use
attenu
rvdz
wellcharacter
wild
type
strain
genotyp
compar
viru
yield
percentag
infect
cell
cell
monolay
infect
viru
strain
high
ffucel
low
ffucel
multipl
infect
moi
high
moi
allow
compar
effici
viru
entri
replic
low
moi
provid
inform
effici
celltocel
spread
moi
day
infect
almost
entir
monolay
produc
infecti
titer
ffuml
lgspnchgpdwaspcqrh
infecti
vaccinederiv
rubella
virus
immunodefici
infecti
vaccinederiv
rubella
virus
immunodefici
replic
rvdz
less
effect
fig
contrast
ivdrv
infect
fewer
cell
monolay
produc
log
less
infecti
viru
depend
isol
similar
rvdz
ivdrv
spread
low
moi
infect
reduc
compar
size
foci
form
ivdrv
vero
monolay
smaller
rvdz
confirm
reduc
abil
ivdrv
spread
cell
cultur
fig
effici
cell
spread
vari
depend
ivdrv
isol
least
effici
rv
rna
replic
singl
cell
level
assess
use
rnafish
cell
mock
infect
infect
rv
strain
moi
two
day
genom
rv
rna
detect
situ
hybrid
probe
set
specif
posit
rna
strand
fig
previous
observ
endotheli
cell
total
amount
genom
rv
rna
per
cell
substanti
higher
rvdz
infect
cell
ivdrv
infect
monolay
cell
produc
low
quantiti
genom
rv
rna
similar
rvdz
isol
cell
produc
somewhat
higher
level
cellular
rv
rna
rvdz
also
observ
fig
abil
ivdrv
isol
persist
cell
compar
high
low
moi
viru
titer
medium
cytopath
effect
cpe
monitor
day
substanti
differ
seen
persist
characterist
differ
moi
initi
peak
replic
start
day
began
induc
cell
death
result
complet
destruct
monolay
dpi
moi
dpi
moi
fig
contrast
rvdz
persist
level
ffuml
durat
experi
without
caus
visibl
cpe
continu
viru
product
similar
rvdz
unlik
rvdz
virus
induc
cpe
start
dpi
result
reduct
cell
number
dpi
cell
rvposit
infect
monolay
dpi
except
infect
fraction
infect
cell
reduc
initi
less
dpi
concurr
titer
reduct
viru
product
consist
low
ffuml
infect
cell
detect
dpi
consensu
genom
sequenc
ivdrv
dpi
ident
consensu
sequenc
initi
inoculum
although
minor
fraction
differ
variant
would
detect
sanger
sequenc
result
analys
clearli
indic
ivdrv
isol
uniqu
replic
persist
properti
differ
vaccin
wtrv
notabl
ivdrv
isol
less
cytopath
cell
cultur
capabl
persist
indic
least
partial
wt
phenotyp
cell
cultur
immun
vaccin
strain
protect
infect
differ
rv
genotyp
howev
mutat
spectra
ivdrv
wtrv
differ
substanti
tabl
evalu
protect
capac
rubella
vaccin
ivdrv
strain
compar
neutral
titer
sera
healthi
adult
vaccine
four
ivdrv
strain
gener
vaccine
sera
contain
rv
neutral
antibodi
could
better
neutral
rel
ivdrv
except
fig
isol
resist
neutral
sinc
sera
fail
effect
neutral
data
suggest
addit
research
immun
respons
vaccin
individu
ivdrv
warrant
next
examin
rubella
antibodi
titer
neutral
titer
ivdrv
strain
serum
sampl
three
pid
granuloma
case
case
patient
supplement
immunoglobulin
therapi
thu
patient
sera
presum
contain
mixtur
rv
antibodi
produc
immun
system
infus
ca
la
case
patient
intraven
igg
ivig
therapi
rv
igg
titer
substanti
higher
typic
vaccine
titer
iuml
ri
case
patient
intramuscular
immunoglobulin
therapi
imig
rv
igg
titer
compar
vaccine
tabl
neutral
titer
three
patient
three
ivdrv
strain
substanti
higher
compar
typic
neutral
titer
less
iuml
vaccin
individu
tabl
nonetheless
high
level
neutral
antibodi
suffici
elimin
persist
ivdrv
skin
notabl
serum
sampl
ca
ri
case
patient
posit
rv
igm
antibodi
tabl
neg
measl
studi
report
isol
infecti
ivdrv
strain
cutan
granulomat
lesion
four
pid
patient
describ
genet
characterist
overal
characterist
molecular
evolut
replic
properti
immunolog
properti
first
attempt
recov
infecti
rubella
viru
skin
lesion
singl
pid
patient
unsuccess
success
viru
isol
time
may
attribut
combin
two
factor
use
optim
viru
cultur
procedur
presenc
less
diverg
ivdrv
strain
case
describ
compar
previous
report
case
one
key
find
studi
discoveri
test
granuloma
contain
infecti
ivdrv
differ
biolog
properti
tissu
cultur
compar
parent
vaccin
viru
remark
featur
isol
ivdrv
chang
cytocid
characterist
tissu
cultur
cell
deriv
fibroblast
presum
initi
target
replic
subcutan
vaccin
notabl
cytopath
fibroblast
wherea
wt
rv
strain
cytopath
cell
type
test
includ
fibroblast
establish
longterm
persist
infect
unfortun
easili
avail
anim
model
rubella
viru
patholog
exist
thu
extend
tissu
cultur
result
like
requir
natur
histori
studi
pid
patient
normal
individu
infecti
vaccinederiv
rubella
virus
immunodefici
vaccin
chang
tissu
tropism
ivdrv
would
signific
observ
especi
evid
transmiss
normal
individu
found
whole
genom
sequenc
reveal
recov
virus
contain
multipl
predominantli
virusspecif
nucleotid
amino
acid
substitut
respect
give
molecular
basi
differ
biolog
properti
vaccin
viru
estim
overal
evolutionari
rate
ivdrv
x
subssit
year
base
whole
genom
sequenc
consist
evolutionari
rate
report
small
rna
virus
somewhat
higher
report
wtrv
genotyp
subssiteyear
popul
persontoperson
transmiss
higher
ivdrv
evolut
rate
may
due
continu
viral
replic
select
chronic
infect
singl
individu
oppos
intermitt
replic
select
diseas
outbreak
also
document
first
time
ivdrv
persist
lesion
divers
popul
heterogen
close
relat
quasispeci
mani
persist
rna
virus
maintain
host
quasispeci
high
quasispeci
complex
allow
virus
quickli
adapt
chang
condit
within
host
thu
repres
challeng
antivir
therapi
eg
select
drugresist
viru
variant
inde
mutant
spectrum
complex
could
factor
predict
diseas
progress
respons
antivir
coexist
two
genet
distinct
quasispeci
subpopul
ca
patient
granuloma
two
ivdrv
lineag
np
caviti
skin
lesion
la
patient
report
suggest
viral
popul
structur
chronic
infect
patient
could
complic
current
appreci
distinct
lineag
site
persist
lack
viremia
indic
viru
spread
local
celltocel
spread
perhap
circul
viru
viremia
effect
neutral
high
level
rv
neutral
antibodi
detect
patient
granuloma
often
present
multipl
bodi
locat
skin
well
intern
organ
eg
liver
kidney
spleen
would
interest
compar
viru
sequenc
multipl
granuloma
site
patient
verifi
multipl
ivdrv
lineag
may
persist
evolv
independ
differ
bodi
site
whether
recombin
lineag
occur
compartment
genet
possibl
antigen
distinct
viral
subpopul
report
number
virus
includ
hepat
c
hiv
may
contribut
mainten
persist
infect
errorpron
rdrp
certainli
major
contributor
gener
sequenc
divers
mani
small
rna
virus
howev
studi
provid
evid
cellular
factor
one
tcnspecif
apobec
adar
promin
sourc
mutat
persist
ivdrv
genom
fig
increas
genet
divers
thu
particip
ivdrv
evolut
interestingli
high
level
express
gene
ctou
rna
edit
activ
subset
cellular
rna
detect
monocyt
macrophag
one
target
cell
rv
granuloma
pid
patient
rna
edit
host
adar
system
propos
factor
evolut
mani
posit
negativesens
rna
virus
wherea
abil
famili
member
restrict
viral
replic
report
four
rna
virus
measl
mump
respiratori
syncyti
viru
coronaviru
inhibit
viral
replic
virus
demonstr
vitro
cell
cultur
overexpress
apobec
protein
mediat
apobec
activ
cytidin
deamin
knowledg
report
first
studi
describ
mrna
edit
signatur
apobec
genom
rna
viru
longterm
persist
vivo
howev
studi
need
assign
rv
rna
edit
activ
specif
member
apobec
famili
effect
ivdrv
popul
size
granuloma
expect
smaller
seen
viral
infect
given
low
quantiti
genom
rv
rna
biopsi
given
small
foci
infect
consist
sever
infect
cell
ihc
pid
associ
granuloma
therefor
expect
persist
ivdrv
undergo
sequenti
genet
bottleneck
limit
number
founder
virus
spread
within
host
gener
independ
viru
popul
differ
locat
linear
accumul
substitut
synonym
nonsynonym
ivdrv
genom
differ
individu
differ
bodi
site
period
persist
compat
predict
random
genet
drift
main
forc
drive
ivdrv
genom
evolut
least
chronic
phase
infect
anoth
known
consequ
genet
drift
appear
numer
atyp
mutat
could
molecular
basi
fit
loss
persist
virus
inde
major
amino
acid
substitut
specif
ivdrv
strain
mani
occur
posit
invari
wtrv
eg
mutat
highli
conserv
methyltransferas
domain
rdrp
catalyt
domain
tabl
strong
neg
select
observ
nonstructur
protein
evidenc
dnd
ratio
less
structur
protein
less
constrain
conserv
c
consist
data
obtain
evolut
wtrv
immunolog
compet
individu
also
identifi
sever
possibl
region
posit
select
mutat
b
cell
epitop
tabl
sinc
adapt
evolut
virus
often
strongli
coupl
antigen
evolut
reason
suggest
mutat
predict
b
tcell
epitop
ivdrv
posit
select
combin
immun
pressur
immunoglobulin
therapi
ongo
cellular
humor
immun
respons
patient
data
poor
neutral
ivdrv
strain
sera
vaccin
individu
support
hypothesi
emerg
immun
escap
variant
might
one
mechan
ivdrv
persist
howev
discrep
presenc
mutat
neutral
epitop
abil
ivdrv
avoid
neutral
vaccine
sera
exampl
viru
resist
neutral
mutat
known
epitop
wherea
mutat
known
epitop
neutral
effect
like
possibl
neutral
site
rv
identifi
number
known
ctl
epitop
also
small
three
ctl
epitop
c
protein
report
known
extent
sequenc
variabl
epitop
toler
overal
poor
understand
antigen
structur
vaccin
wtrv
strain
hamper
investig
possibl
mechan
ivdrv
escap
immun
surveil
contribut
ivdrv
persist
one
puzzl
observ
detect
extrem
high
titer
rv
neutral
antibodi
pid
patient
sera
observ
lack
viremia
three
test
patient
like
due
continu
remov
ivdrv
bloodstream
neutral
antibodi
present
unknown
whether
neutral
antibodi
origin
supplement
immunoglobulin
therapi
produc
immun
system
chronic
infect
patient
rv
neutral
titer
rang
report
commerci
lot
immunoglobulin
produc
prior
introduct
rubella
vaccin
determin
rv
neutral
titer
current
produc
immunoglobulin
prepar
sequenti
serum
sampl
collect
differ
time
initi
immunoglobulin
therapi
may
help
defin
contribut
ivig
therapi
patient
immun
system
neutral
capac
patient
sera
work
would
like
enhanc
understand
role
antibodi
clearanc
rv
chronic
infect
addit
detect
high
level
neutral
antibodi
also
detect
rvspecif
igm
antibodi
measl
mump
specif
igm
sera
two
pid
patient
unlik
rvspecif
igm
antibodi
ivig
therapi
sinc
commerci
immunoglobulin
product
contain
primarili
igg
plasma
thousand
healthi
blood
donor
trace
amount
igm
investig
rv
igm
level
larger
group
pid
patient
consid
evalu
whether
persist
rv
igm
respons
long
vaccin
may
serv
marker
ongo
rv
replic
may
predict
granuloma
format
prior
develop
lesion
similarli
hepat
c
specif
igm
antibodi
observ
patient
chronic
hepat
level
correl
level
viral
replic
treatment
outcom
detect
ivdrv
rna
nasopharyng
secret
rais
concern
possibl
risk
ivdrv
nonimmun
individu
sinc
low
level
rv
rna
detect
sequenti
np
sampl
one
case
three
test
risk
may
low
frequenc
intens
viru
secret
np
caviti
well
transmiss
virus
nonimmun
contact
determin
larger
studi
group
us
estim
individu
pid
granuloma
complic
thu
may
potenti
ivdrv
carrier
longterm
ivdrv
secret
individu
may
implic
rubella
cr
elimin
program
even
ivdrv
carrier
shed
low
viru
quantiti
opportun
transmit
viru
suscept
contact
includ
nonimmun
sibl
patient
pid
clinic
may
occur
decadeslong
ivdrv
persist
one
limit
studi
use
diagnost
skin
sampl
one
per
patient
collect
differ
time
vaccin
rather
multipl
sampl
patient
collect
serial
time
would
use
studi
pathogen
evolut
within
patient
detail
understand
rubella
viru
persist
pid
patient
requir
part
accumul
inform
virus
patient
serial
sampl
individu
patient
unfortun
reliabl
specimen
far
known
ivdrv
isol
sequenc
skin
biopsi
obtain
sequenti
skin
sampl
pid
patient
children
extend
period
time
would
challeng
would
requir
human
subject
oversight
appropri
research
studi
nonetheless
import
conclus
regard
overal
trend
ivdrv
evolut
within
pid
host
properti
persist
ivdrv
drawn
analysi
limit
number
diagnost
biopsi
sampl
describ
alreadi
find
intrigu
pid
patient
rv
posit
persist
granuloma
defect
cellular
immun
find
mutat
tcell
epitop
virus
furthermor
tcell
exhaust
known
import
chronic
viral
infect
hypothes
cellular
immun
defect
delay
viral
clearanc
exacerb
would
limit
persist
infect
person
normal
immun
lead
year
decad
long
infect
result
damag
multipl
tissu
pid
individu
howev
note
limit
exist
data
leav
open
possibl
factor
eg
chang
tissu
tropism
viru
antibodi
escap
mutant
crucial
factor
determin
extend
persist
addit
sinc
import
properti
rubella
virus
teratogen
potenti
poorli
understood
accur
predict
effect
mutat
found
teratogen
potenti
tissu
cultur
result
present
diseas
associ
ivdrv
sequenc
variat
ivdrv
describ
compar
prolong
viral
infect
immunocompromis
person
similar
signific
differ
found
number
person
pid
prolong
excret
vaccinederiv
polioviru
ivdpv
global
around
past
year
case
report
individu
diseasedeath
associ
chronic
polio
vaccin
replic
thousand
person
current
cutan
granuloma
associ
ivdrv
predict
unit
state
alon
associ
rv
granulomat
diseas
establish
blind
studi
median
excret
time
prolong
polioviru
pid
year
compar
decadeslong
rv
replic
granuloma
influenza
viru
infect
immunocompromis
patient
eg
transplant
patient
becom
chronic
month
viru
usual
clear
comparison
sequenc
diverg
virus
differ
replic
properti
genom
sequenc
stabil
usual
limit
util
nevertheless
parallel
observ
ivdrv
genom
evolut
chronic
rna
viru
infect
exampl
genom
polioviru
influenza
viru
also
purifi
select
select
specif
chang
found
well
polioviru
accumul
mutat
genet
rearrang
like
increas
chanc
revers
neurovirul
strain
immunocompromis
person
still
vaccinelik
report
chang
ivdrv
cytopatholog
characterist
lack
anim
model
rubella
viru
induc
patholog
limit
evalu
signific
tissu
cultur
find
experiment
set
influenza
viru
recent
report
parallel
evolut
virus
immunocompromis
person
global
circul
intrigu
sinc
ivdrv
known
circul
import
parallel
report
unlik
report
differ
mutat
ivdrv
chang
wild
type
virus
tabl
signific
differ
requir
analysi
sequenc
addit
unfortun
molecular
surveil
rubella
virus
far
inferior
influenza
viru
polioviru
also
signific
constraint
test
similar
parallel
evolut
rubella
virus
pid
patient
conclus
studi
provid
first
evid
presenc
infecti
vaccin
deriv
rubella
virus
granuloma
pid
patient
evid
rv
genom
rna
np
caviti
result
strongli
indic
ongo
replic
evolut
rubella
vaccin
pid
person
result
emerg
ivdrv
strain
biolog
properti
distinct
knowledg
first
studi
detail
mrna
edit
signatur
associ
apobec
enzym
rna
viru
furthermor
provid
evid
ivdrv
genom
neg
select
random
genet
drift
primari
mechan
evolut
ivdrv
genom
posit
select
play
role
result
may
provid
inform
use
design
therapi
pid
patient
granuloma
associ
rubella
vaccin
final
persist
rubella
viru
occur
number
seriou
diseas
eg
cr
fuch
uveiti
find
persist
rubella
viru
vaccin
replic
pid
may
use
understand
rubella
virusassoci
diseas
detail
case
descript
publish
separ
briefli
four
patient
receiv
mmr
vaccin
one
year
age
one
patient
receiv
second
dose
age
case
three
patient
diagnos
ataxia
telangiectasia
one
patient
diagnosi
nijmegen
breakag
syndrom
tabl
develop
cutan
granulomat
lesion
differ
bodi
site
eg
face
chest
arm
leg
variou
time
vaccin
pathogen
organ
identifi
histochem
stain
bacteri
fungal
mycobacteri
cultur
ca
la
case
patient
ivig
therapi
ri
case
patient
receiv
imig
everi
week
topic
system
administr
antiinflammatori
drug
igg
therapi
patient
result
signific
clinic
improv
ri
case
patient
deceas
age
year
type
specimen
collect
diagnost
purpos
time
collect
indic
tabl
patient
punch
biopsi
taken
affect
skin
immedi
snap
frozen
liquid
nitrogen
store
test
slide
cut
archiv
formalinfix
paraffinembed
ffpe
tissu
block
skin
biopsi
la
ri
case
patient
also
submit
cdc
test
diagnost
sampl
obtain
provis
written
inform
consent
ca
ri
la
case
attend
physician
verbal
consent
obtain
case
patient
parent
diagnost
skin
biopsi
document
patient
chart
standard
oregon
health
scienc
univers
minim
risk
procedur
sampl
submit
rubella
laboratori
cdc
atlanta
usa
state
public
health
laboratori
molecular
test
viru
cultur
rubella
serolog
perform
part
refer
surveil
respons
cdc
laboratori
sinc
rv
analys
conduct
purpos
public
health
respons
work
determin
research
human
cdc
institut
review
board
project
determin
number
serum
sampl
healthi
individu
mmr
immun
histori
collect
emori
univers
donor
servic
written
consent
obtain
particip
vero
cell
atcc
human
primari
fetal
fibroblast
coriel
institut
camden
nj
maintain
dmem
supplement
fetal
bovin
serum
fb
atlanta
biolog
respect
half
snapfrozen
skin
biopsi
use
viru
cultur
half
rna
isol
see
skin
tissu
homogen
ml
fb
antibioticantimycot
invitrogen
use
zirconium
bead
describ
elsewher
tissu
homogen
materi
swab
inocul
subconflu
vero
cell
monolay
tissu
cultur
flask
viru
adsorb
h
ml
fb
ad
flask
medium
replac
next
day
sinc
rv
typic
cytopath
vero
cell
instead
use
standard
protocol
three
blind
passag
cultur
media
cell
transfer
passag
day
flask
one
week
cultiv
similarli
addit
week
cell
flask
transfer
flask
incub
third
week
modifi
viru
isol
techniqu
allow
improv
recoveri
infecti
viru
sampl
contain
low
amount
rv
monitor
amount
infect
cell
cell
seed
chamber
slide
transfer
cell
larger
flask
immunostain
rubella
structur
protein
use
mous
monoclon
antibodi
describ
previous
presenc
rv
rna
cultur
media
monitor
real
time
rtqpcr
depend
viru
concentr
media
viru
stock
harvest
either
day
day
prepar
high
titer
stock
rvdz
genotyp
use
bioreactor
describ
elsewher
ivdrv
isol
passag
vero
cell
three
addit
time
use
standard
protocol
high
titer
viru
stock
prepar
concentr
infect
cell
media
jumbosep
centrifug
devic
pall
life
scienc
accord
manufactur
instruct
virus
titer
vero
cell
foci
infect
detect
immunocolorimetr
assay
rubella
igg
titer
measur
enzymelink
immunosorb
assay
eia
zeu
elisa
rubella
igg
test
system
zeu
scientif
branchburg
nj
accord
manufactur
instruct
express
iuml
rubella
igm
test
perform
rubella
igm
captur
eia
kit
diamedix
miami
fl
measl
mump
igm
test
perform
use
inhous
captur
igm
eia
assay
vero
cell
seed
plate
cellswel
next
day
cell
monolay
infect
rv
strain
moi
ffucel
ffucel
three
experi
two
replic
well
per
viru
strain
follow
adsorpt
unbound
viru
wash
away
three
chang
hbss
ml
fresh
medium
ad
infect
monolay
viru
titer
medium
determin
titrat
vero
cell
use
immunocolorimetr
assay
cell
monolay
fix
methanol
stain
immunofluoresc
assay
percentag
infect
cell
determin
previous
describ
cell
monolay
plate
mock
infect
infect
rv
strain
describ
two
experi
two
replic
well
per
viru
strain
viru
adsorpt
hbss
wash
initi
medium
sampl
hpi
collect
minut
fresh
medium
addit
subsequ
medium
sampl
collect
interv
viru
collect
medium
sampl
titer
vero
cell
duplic
dpi
phase
contrast
imag
taken
fluoresc
invert
microscop
zeiss
oberkochen
germani
remain
cell
mock
infect
infect
well
collect
trypsin
count
use
scepter
cell
counter
millipor
billerica
cell
polylysin
coat
chamber
slide
bd
bioscienc
mock
infect
infect
rv
strain
moi
two
experi
two
replic
well
per
viru
strain
rv
genom
rna
detect
posit
strandspecif
probe
set
use
quantigen
viewrna
assay
kit
affymetrix
cat
previous
describ
presenc
rubella
antigen
ffpe
tissu
section
detect
histolog
immunofluoresc
stain
describ
previous
twofold
serial
dilut
heatinactiv
serum
sampl
prepar
rang
mixtur
serum
dilut
viru
strain
ffu
incub
hour
ad
vero
cell
monolay
plate
follow
viru
adsorpt
cell
overlaid
dmem
thermo
fisher
fb
avicel
fmc
biopolym
newark
de
incub
co
pool
serum
sampl
vaccine
rubella
igm
igg
seroconvers
panel
biomex
gmbh
heidelberg
germani
serv
posit
control
assay
serum
sampl
donor
lack
rv
neutral
antibodi
includ
assay
neg
control
infect
cell
immunostain
dpi
dpi
dpi
dpi
describ
foci
infect
count
use
elispot
analyz
ctl
cleveland
oh
neutral
titer
serum
sampl
express
reciproc
dilut
serum
neutral
ad
viru
calcul
doserespons
regress
analysi
use
graphpad
prism
softwar
graphpad
softwar
inc
san
diego
ca
rna
isol
snap
frozen
skin
sampl
use
rneasi
fibrou
tissu
mini
kit
qiagen
swab
sampl
cultur
media
use
qiaamp
viral
rna
mini
kit
qiagen
accord
manufactur
instruct
quantit
realtim
rtqpcr
rubella
measl
mump
virus
describ
elsewher
detail
descript
fullgenom
sequenc
strategi
rubella
viru
publish
briefli
five
overlap
genom
fragment
produc
rtpcr
use
primer
list
tabl
pcr
fragment
sequenc
sanger
method
sequenc
genom
end
determin
use
race
kit
direct
manufactur
roch
diagnost
mannheim
germani
sequenc
name
accord
rv
name
convent
modif
rv
prefix
use
design
sequenc
obtain
total
rna
isol
clinic
sampl
rvi
prefix
use
design
sequenc
obtain
recov
rv
isol
epi
week
name
indic
date
sampl
collect
instead
onset
date
addit
gr
np
indic
sequenc
origin
granuloma
np
swab
respect
sequenc
align
use
muscl
algorithm
align
annot
accord
genom
use
geneiou
softwar
version
biomatt
ltd
phylogenet
analys
perform
softwar
number
synonym
substitut
per
synonym
site
ds
nonsynonym
substitut
per
nonsynonym
site
dn
dnd
ratio
averag
behavior
codon
synonym
nonsynonym
mutat
calcul
pairwis
comparison
ivdrv
rv
sequenc
ancestor
sequenc
method
nei
gojobori
use
synonym
nonsynonym
analysi
program
snap
http
wwwhivlanlgov
contentsequencesnapsnaphtml
program
adjust
multipl
hit
use
jukescantor
correct
fragment
gene
nt
rv
genom
amplifi
rna
isol
clinic
sampl
viral
stock
use
rv
genotyp
primer
platinum
superfi
dna
polymeras
taq
fidel
thermo
fisher
pcr
fragment
clone
pcrblunt
iitopo
vector
thermo
fisher
plasmid
dna
isol
use
zymopur
plasmid
miniprep
kit
zymo
research
plasmid
insert
sequenc
forward
revers
primer
rv
primer
withinsubject
pairwis
genet
distanc
individu
quasispeci
comput
use
maximum
composit
likelihood
method
complet
sequenc
ivdrv
genom
deposit
ncbi
databas
access
number
structur
rubella
protein
pdb
entri
use
templat
comput
model
mutat
model
describ
earlier
use
softwar
packag
ecmm
energi
calcul
macro
molecular
system
molecular
mechan
model
illustr
protein
structur
prepar
use
ds
visual
http
accelryscomproductscollaborativesciencebioviadiscoverystudio
visualizationhtml
accelri
inc
ca
first
creat
list
mutat
ambigu
nucleotid
exclud
analysi
data
mutat
use
evalu
enrich
apobec
mutat
signatur
predict
score
adar
activ
enrich
mutat
signatur
defin
fold
excess
actual
mutat
count
cytosin
rv
plu
strand
fall
signatur
motif
divid
count
expect
random
mutagenesi
calcul
describ
detail
briefli
calcul
ratio
two
ratio
ratio
number
mutat
cytosin
fall
signaturespecif
trinucleotid
context
total
number
mutat
cytosin
well
ratio
number
signatur
specif
trinucleotid
total
number
cytosin
genom
background
background
consid
area
nucleotid
center
around
mutat
base
column
context
data
supplementari
tabl
note
tabl
display
base
dna
format
allow
compat
comparison
mutat
signatur
output
apobec
mutagenesi
dna
allow
us
minim
possibl
distort
enrich
calcul
influenc
local
rna
secondari
structur
mutagenesi
could
excess
shield
genom
area
apobec
enzym
deamin
cytosin
doubl
strand
structur
exampl
formula
calcul
e
uca
enrich
ie
foldexcess
random
expect
uca
mutat
signatur
mut
uca
mutat
cytosin
fall
uca
motif
posit
strand
viru
isol
con
uca
uca
trinucleotid
motif
nucleotid
sequenc
posit
strand
center
around
mutat
posit
strand
cytosin
base
mut
c
mutat
cytosin
posit
strand
viru
isol
con
c
c
nucleotid
nucleotid
sequenc
posit
strand
center
around
mutat
posit
strand
cytosin
base
unlik
exquisit
specif
singl
strand
rna
dna
apobec
cytidin
deaminas
adar
act
adenin
imbed
doubl
strand
rna
fold
predict
adar
deamin
site
account
combin
knowledg
experiment
defin
short
nucleotid
motif
potenti
form
doubl
strand
structur
predict
score
adar
activ
adenin
gener
use
webbas
tool
inosinepredict
http
onesid
mannwhitney
test
predict
score
test
hypothesi
score
atog
chang
characterist
adar
would
exceed
score
atog
nucleotid
perform
obtain
pvalu
shown
scatter
plot
